 |
|
|
| |
A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients
With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Kosh Agarwal,1 Scott Fung,2 Wai Kay Seto,3 Young-Suk Lim,4 Edward Gane,5 Harry L.A. Janssen,6 Manoj Sharma,7 Wan-Long Chuang,8 Ho Bae,9 Ki Tae Yoon,10 John F. Flaherty,11
Audrey Lau,11 Anuj Gaggar,11 Vithika Suri,11 Andrea Cathcart,11 Lanjia Lin,11 G Mani Subramanian,11 Shalimar,12 Norihiro Furusyo,13 Maria Buti,14 Henry L.Y. Chan15
1King's College Hospital, London, UK; 2Toronto General Hospital, Toronto, Ontario, Canada; 3Queen Mary Hospital, Hong Kong; 4ASAN Medical Center, Seoul, South Korea; 5Auckland Clinical Studies, Auckland, New Zealand; 6Toronto Western Hospital, Toronto, and Erasmus MC, Rotterdam, the Netherlands; 7Institute of Liver & Biliary Sciences, New Delhi, India; 8Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan; 9Asian Pacific Liver Center, Los Angeles, California, USA; 10Pusan National University Yangsan Hospital, Yangsan-si, South Korea; 11Gilead Sciences, Inc., Foster City, California; 12All India Institute of Medical Sciences, New Delhi, India; 13Kyushu Medical Center, Fukuoka, Japan; 14Vall d'Hebron Hospital, Barcelona, Spain; 15The Chinese University of Hong Kong
EASL: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96 - (04/26/17)
EASL: Continued Improvement in Renal Laboratory Parameters in CHB Patients Treated With Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate Over 96 Weeks - (05/05/17)
EASL: DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: a prospective Greek study - (04/26/17)
EASL: Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Preliminary Results From 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B - (04/26/17)
CROI: TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)
APASL: Improved Renal Laboratory Parameters in Chronic HBV (CHB) Patients Treated With Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (03/15/17)
European Commission Grants Marketing Authorization for Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection - (01/18/17)
HBV Reactivation on DAAs - Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals - (01/09/17)
|
| |
|
|
|
|
|
